Story

Apnimed Stock Surges on Bullish Initiations from BofA, Cantor Fitzgerald

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20262 min read
Apnimed Stock Surges on Bullish Initiations from BofA, Cantor Fitzgerald
Text size
Background

Apnimed (APMD) shares surged more than 11% in morning trading after two prominent Wall Street firms initiated coverage with bullish ratings, citing a favorable entry point and significant upside potential for the company's lead drug candidate.

Dual Upgrades Spark Rally

The rally was triggered by new research coverage from both BofA Securities and Cantor Fitzgerald, according to a report from Investing.com. The timing proved potent, as the initiations followed a week where Apnimed's stock had declined by approximately 19%.

  • BofA Securities started coverage with a Buy rating and a $41 price target, based on a discounted cash flow analysis of the company's main drug candidate.
  • Cantor Fitzgerald assigned an Overweight rating with a $60 price target, using a similar valuation model that implied roughly double the stock's value at the time of initiation.

Focus on Sleep Apnea Drug Oxnimbi

Both firms' positive outlook is centered on Oxnimbi (AD109), Apnimed's investigational oral therapy for obstructive sleep apnea (OSA). The drug faces a critical regulatory milestone, with the U.S. Food and Drug Administration (FDA) setting a Prescription Drug User Fee Act (PDUFA) goal date of February 28, 2027.

Sample IUX Markets – In-articleAd

If approved, Oxnimbi would represent a significant development in the OSA market, which is currently dominated by medical devices like CPAP machines and surgical procedures. It would become one of the few pharmacological treatments available, entering a market that also includes therapies like Eli Lilly’s Zepbound.

Market Reaction

Apnimed's stock rose as much as 11.9% on the news, hitting a session high of $29.56 before settling slightly lower. The sharp, company-specific move far outpaced the broader market, which saw modest gains with the S&P 500 up approximately 0.2%.

The combination of fresh institutional attention, a recent pullback in the share price, and a clear upcoming regulatory catalyst created the conditions for Tuesday's strong performance.

Read next

More on Stocks
Back to latest news

LATEST